Kallikrein-related peptidases in prostate, breast, and ovarian cancers: From pathobiology to clinical relevance

Biological Chemistry

Volumn 393, Issue 5, 2012, Pages 301-317

  Avgeris, Margaritis ^a   Mavridis, Konstantinos ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biomarkers; Epithelial mesenchymal transition; Extracellular matrix proteases; KLK; PSA; Serine proteases

Indexed keywords

ANTIANDROGEN; DESMOCOLLIN; DESMOGLEIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; KALLIKREIN; KALLIKREIN 1; KALLIKREIN 10; KALLIKREIN 14; KALLIKREIN 15; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; PLASMA KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; REACTIVE OXYGEN METABOLITE; SMAD2 PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; STAT3 PROTEIN; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BIOAVAILABILITY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; DEMETHYLATION; DIAGNOSTIC VALUE; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; MICROENVIRONMENT; OVARY CANCER; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

BREAST NEOPLASMS; FEMALE; HUMANS; KALLIKREINS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 84859810060     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2011-0260     Document Type: Conference Paper

References (187)

1. Adams, M.N., Ramachandran, R., Yau, M.K., Suen, J.Y., Fairlie, D.P., Hollenberg, M.D., and Hooper, J.D. (2011). Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130, 248-282.
2. Andriole, G.L., Crawford, E.D., Grubb, R.L., 3rd, Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., Gelmann, E.P., Kvale, P.A., Reding, D.J., et al. (2009). Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319.
3. Avgeris, M., Mavridis, K., and Scorilas, A. (2010). Kallikreinrelated peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol. Chem. 391, 505-511.
4. Avgeris, M., Papachristopoulou, G., Polychronis, A., and Scorilas, A. (2011a). Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin. Proteomics 8, 5.
5. Avgeris, M., Stravodimos, K., and Scorilas, A. (2011b). Kallikreinrelated peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. Prostate 71, 1780-1789.
6. Batra, J., Tan, O.L., O'Mara, T., Zammit, R., Nagle, C.M., Clements, J.A., Kedda, M.A., and Spurdle, A.B. (2010). Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival. Int. J. Gynecol. Cancer 20, 529-536.
7. Bayani, J., Paliouras, M., Planque, C., Shan, S.J., Graham, C., Squire, J.A., and Diamandis, E.P. (2008). Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Mol. Oncol. 2, 250-260.
8. Bayani, J., Marrano, P., Graham, C., Zheng, Y., Li, L., Katsaros, D., Lassus, H., Butzow, R., Squire, J.A., and Diamandis, E.P. (2011). Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. Mol. Oncol. 5, 48-60.
9. Bayes, A., Tsetsenis, T., Ventura, S., Vendrell, J., Aviles, F.X., and Sotiropoulou, G. (2004). Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol. Chem. 385, 517-524. (Pubitemid 38967780)
10. Beaufort, N., Debela, M., Creutzburg, S., Kellermann, J., Bode, W., Schmitt, M., Pidard, D., and Magdolen, V. (2006). Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinasetype plasminogen activator receptor (uPAR). Biol. Chem. 387, 217-222. (Pubitemid 43221836)
11. Bernett, M.J., Blaber, S.I., Scarisbrick, I.A., Dhanarajan, P., Thompson, S.M., and Blaber, M. (2002). Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562-24570. (Pubitemid 34951983)
12. Bhoola, K.D., Figueroa, C.D., and Worthy, K. (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80.
13. Bi, X., He, H., Ye, Y., Dai, Q., Han, Z., Liang, Y., and Zhong, W. (2010). Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Med. Oncol. 27, 145-151.
14. Black, M.H., Giai, M., Ponzone, R., Sismondi, P., Yu, H., and Diamandis, E.P. (2000). Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin. Cancer Res. 6, 467-473. (Pubitemid 30111465)
15. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890. (Pubitemid 39472954)
16. Borgono, C.A., Fracchioli, S., Yousef, G.M., Rigault de la Longrais, I.A., Luo, L.Y., Soosaipillai, A., Puopolo, M., Grass, L., Scorilas, A., Diamandis, E.P., et al. (2003a). Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int. J. Cancer 106, 605-610. (Pubitemid 36966221)
17. Borgono, C.A., Grass, L., Soosaipillai, A., Yousef, G.M., Petraki, C.D., Howarth, D.H., Fracchioli, S., Katsaros, D., and Diamandis, E.P. (2003b). Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 63, 9032-9041. (Pubitemid 38064085)
18. Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280. (Pubitemid 39031076)
19. Borgono, C.A., Kishi, T., Scorilas, A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., and Diamandis, E.P. (2006). Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin. Cancer Res. 12, 1487-1493.
20. Borgono, C.A., Michael, I.P., Komatsu, N., Jayakumar, A., Kapadia, R., Clayman, G.L., Sotiropoulou, G., and Diamandis, E.P. (2007a). A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282, 3640-3652. (Pubitemid 47084449)
21. Borgono, C.A., Michael, I.P., Shaw, J.L., Luo, L.Y., Ghosh, M.C., Soosaipillai, A., Grass, L., Katsaros, D., and Diamandis, E.P. (2007b). Expression and functional characterization of the cancerrelated serine protease, human tissue kallikrein 14. J. Biol. Chem. 282, 2405-2422. (Pubitemid 47076761)
22. Catalona, W.J., Smith, D.S., Wolfert, R.L., Wang, T.J., Rittenhouse, H.G., Ratliff, T.L., and Nadler, R.B. (1995). Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274, 1214-1220.
23. Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, J.P., deKernion, J.B., Walsh, P.C., Scardino, P.T., et al. (1998). Use of the percentage of free prostate- specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542-1547. (Pubitemid 28233009)
24. Chang, A., Yousef, G.M., Scorilas, A., Grass, L., Sismondi, P., Ponzone, R., and Diamandis, E.P. (2002). Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br. J. Cancer 86, 1457-1464. (Pubitemid 34548070)
25. Chow, T.F., Crow, M., Earle, T., El-Said, H., Diamandis, E.P., and Yousef, G.M. (2008). Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol. Chem. 389, 731-738. (Pubitemid 352009404)
26. Cramer, S.D., Chen, Z., and Peehl, D.M. (1996). Prostate specific antigen cleaves parathyroid hormone-related protein in the PTHlike domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156, 526-531. (Pubitemid 126445373)
27. Dallas, S.L., Zhao, S., Cramer, S.D., Chen, Z., Peehl, D.M., and Bonewald, L.F. (2005). Preferential production of latent transforming growth factor β-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J. Cell. Physiol. 202, 361-370. (Pubitemid 40041306)
28. Deperthes, D., Frenette, G., Brillard-Bourdet, M., Bourgeois, L., Gauthier, F., Tremblay, R.R., and Dube, J.Y. (1996). Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J. Androl. 17, 659-665. (Pubitemid 27014431)
29. Diamandis, E.P., Yousef, G.M., Soosaipillai, A.R., and Bunting, P. (2000). Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem. 33, 579-583. (Pubitemid 32012441)
30. Diamandis, E.P., Okui, A., Mitsui, S., Luo, L.Y., Soosaipillai, A., Grass, L., Nakamura, T., Howarth, D.J., and Yamaguchi, N. (2002). Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 62, 295-300. (Pubitemid 34074018)
31. Diamandis, E.P., Borgono, C.A., Scorilas, A., Yousef, G.M., Harbeck, N., Dorn, J., Schmalfeldt, B., and Schmitt, M. (2003a). Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol. 24, 299-309. (Pubitemid 38327992)
32. Diamandis, E.P., Scorilas, A., Fracchioli, S., Van Gramberen, M., De Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G.M., Stenman, U.H., et al. (2003b). Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21, 1035-1043. (Pubitemid 46594132)
33. Diamandis, E.P., Borgono, C.A., Scorilas, A., Harbeck, N., Dorn, J., and Schmitt, M. (2004). Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clin. Biochem. 37, 823-829. (Pubitemid 39141126)
34. Dong, Y., Kaushal, A., Brattsand, M., Nicklin, J., and Clements, J.A. (2003). Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin. Cancer Res. 9, 1710-1720. (Pubitemid 36554595)
35. Dong, Y., Tan, O.L., Loessner, D., Stephens, C., Walpole, C., Boyle, G.M., Parsons, P.G., and Clements, J.A. (2010). Kallikrein-related peptidase 7 promotes multicellular aggregation via the α(5)β(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res. 70, 2624-2633.
36. Dorn, J., Harbeck, N., Kates, R., Gkazepis, A., Scorilas, A., Soosaipillai, A., Diamandis, E., Kiechle, M., Schmalfeldt, B., and Schmitt, M. (2011a). Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann. Oncol. 22, 877-883.
37. Dorn, J., Magdolen, V., Gkazepis, A., Gerte, T., Harlozinska, A., Sedlaczek, P., Diamandis, E.P., Schuster, T., Harbeck, N., Kiechle, M., et al. (2011b). Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. Ann. Oncol. 22, 1783-1790.
38. El Sherbini, M.A., Sallam, M.M., Shaban, E.A., and El-Shalakany, A.H. (2011). Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. Int. J. Gynecol. Cancer 21, 625-632.
39. Emami, N. and Diamandis, E.P. (2007). New insights into the functional mechanisms and clinical applications of the kallikreinrelated peptidase family. Mol. Oncol. 1, 269-287. (Pubitemid 350181645)
40. Emanueli, C., Minasi, A., Zacheo, A., Chao, J., Chao, L., Salis, M.B., Straino, S., Tozzi, M.G., Smith, R., Gaspa, L., et al. (2001). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125-132. (Pubitemid 32050447)
41. Ewan King, L., Li, X., Cheikh Saad Bouh, K., Pedneault, M., and Chu, C.W. (2007). Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin. Biochem. 40, 1057-1062. (Pubitemid 47301790)
42. Foekens, J.A., Diamandis, E.P., Yu, H., Look, M.P., Meijer-van Gelder, M.E., van Putten, W.L., and Klijn, J.G. (1999). Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br. J. Cancer 79, 888-894. (Pubitemid 29082122)
43. Fortier, A.H., Nelson, B.J., Grella, D.K., and Holaday, J.W. (1999). Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91, 1635-1640. (Pubitemid 29479930)
44. Fortier, A.H., Holaday, J.W., Liang, H., Dey, C., Grella, D.K., Holland-Linn, J., Vu, H., Plum, S.M., and Nelson, B.J. (2003). Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56, 212-219. (Pubitemid 36918172)
45. Fritzsche, F., Gansukh, T., Borgono, C.A., Burkhardt, M., Pahl, S., Mayordomo, E., Winzer, K.J., Weichert, W., Denkert, C., Jung, K., et al. (2006). Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. Br. J. Cancer 94, 540-547. (Pubitemid 43289758)
46. Gan, L., Lee, I., Smith, R., Argonza-Barrett, R., Lei, H., McCuaig, J., Moss, P., Paeper, B., and Wang, K. (2000). Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 257, 119-130.
47. Gao, J., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L., and Clements, J.A. (2007). Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 67, 348-360. (Pubitemid 46341076)
48. Gao, L., Smith, R.S., Chen, L.M., Chai, K.X., Chao, L., and Chao, J. (2010). Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol. Chem. 391, 803-812.
49. Giusti, B., Serrati, S., Margheri, F., Papucci, L., Rossi, L., Poggi, F., Magi, A., Del Rosso, A., Cinelli, M., Guiducci, S., et al. (2005). The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 52, 3618-3628. (Pubitemid 41612233)
50. Goya, M., Ishii, G., Miyamoto, S., Hasebe, T., Nagai, K., Yonou, H., Hatano, T., Ogawa, Y., and Ochiai, A. (2006). Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 66, 1573-1584. (Pubitemid 44646349)
51. Goyal, J., Smith, K.M., Cowan, J.M., Wazer, D.E., Lee, S.W., and Band, V. (1998). The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 58, 4782-4786. (Pubitemid 28503667)
52. Guillon-Munos, A., Oikonomopoulou, K., Michel, N., Smith, C.R., Petit-Courty, A., Canepa, S., Reverdiau, P., Heuzé-Vourc'h, N., Diamandis, E.P., and Courty, Y. (2011). Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J. Biol. Chem. 286, 25505-25518.
53. Hakalahti, L., Vihko, P., Henttu, P., Autio-Harmainen, H., Soini, Y., and Vihko, R. (1993). Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer 55, 590-597. (Pubitemid 23328944)
54. Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A., Ashworth, L.K., and Clements, J.A. (2000). Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397-37406. (Pubitemid 32004843)
55. Heidtmann, H.H., Nettelbeck, D.M., Mingels, A., Jager, R., Welker, H.G., and Kontermann, R.E. (1999). Generation of angiostatinlike fragments from plasminogen by prostate-specific antigen. Br. J. Cancer 81, 1269-1273.
56. Hoffman, B.R., Katsaros, D., Scorilas, A., Diamandis, P., Fracchioli, S., Rigault de la Longrais, I.A., Colgan, T., Puopolo, M., Giardina, G., Massobrio, M., et al. (2002). Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer 87, 763-771. (Pubitemid 35178754)
57. Hollenberg, M.D., Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Ramachandran, R., and Diamandis, E.P. (2008). Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol. Chem. 389, 643-651. (Pubitemid 352009410)
58. Hugo, H., Ackland, M.L., Blick, T., Lawrence, M.G., Clements, J.A., Williams, E.D., and Thompson, E.W. (2007). Epithelialmesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 213, 374-383. (Pubitemid 47509716)
59. Ishii, K., Otsuka, T., Iguchi, K., Usui, S., Yamamoto, H., Sugimura, Y., Yoshikawa, K., Hayward, S.W., and Hirano, K. (2004). Evidence that the prostate-specific antigen (PSA)/Zn 2 + axis may play a role in human prostate cancer cell invasion. Cancer Lett. 207, 79-87. (Pubitemid 38429889)
60. Jovanovic, J., Ronneberg, J.A., Tost, J., and Kristensen, V. (2010). The epigenetics of breast cancer. Mol. Oncol. 4, 242-254.
61. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
62. Killian, C.S., Corral, D.A., Kawinski, E., and Constantine, R.I. (1993). Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 192, 940-947. (Pubitemid 23227414)
63. Kim, H., Scorilas, A., Katsaros, D., Yousef, G.M., Massobrio, M., Fracchioli, S., Piccinno, R., Gordini, G., and Diamandis, E.P. (2001). Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer 84, 643-650. (Pubitemid 32238998)
64. Kioulafa, M., Kaklamanis, L., Stathopoulos, E., Mavroudis, D., Georgoulias, V., and Lianidou, E.S. (2009). Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann. Oncol. 20, 1020-1025.
65. Kishi, T., Grass, L., Soosaipillai, A., Scorilas, A., Harbeck, N., Schmalfeldt, B., Dorn, J., Mysliwiec, M., Schmitt, M., and Diamandis, E.P. (2003). Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 63, 2771-2774. (Pubitemid 36667147)
66. Klokk, T.I., Kilander, A., Xi, Z., Waehre, H., Risberg, B., Danielsen, H.E., and Saatcioglu, F. (2007). Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res. 67, 5221-5230. (Pubitemid 46997260)
67. Koh, S.C., Razvi, K., Chan, Y.H., Narasimhan, K., Ilancheran, A., Low, J.J., and Choolani, M. (2011). The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer. Arch. Gynecol. Obstet. 284, 183-190.
68. Koistinen, H., Paju, A., Koistinen, R., Finne, P., Lovgren, J., Wu, P., Seppala, M., and Stenman, U.H. (2002). Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50, 112-118. (Pubitemid 34123700)
69. Korbakis, D., Gregorakis, A.K., and Scorilas, A. (2009). Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clin. Chem. 55, 904-913.
70. Kountourakis, P., Psyrri, A., Scorilas, A., Camp, R., Markakis, S., Kowalski, D., Diamandis, E.P., and Dimopoulos, M.A. (2008). Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Sci. 99, 2224-2229.
71. Kountourakis, P., Psyrri, A., Scorilas, A., Markakis, S., Kowalski, D., Camp, R.L., Diamandis, E.P., and Dimopoulos, M.A. (2009). Expression and prognostic significance of kallikreinrelated peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb. Haemost. 101, 541-546.
72. Kraut, H., Frey, E.K., and Werle, E. (1930). Der Nachweis eines Kreislaufhormons in der Pankreasdrüse. Hoppe-Seyler's Z Physiol. Chem. 189, 97-106.
73. Kuzmanov, U., Jiang, N., Smith, C.R., Soosaipillai, A., and Diamandis, E.P. (2009). Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol. Cell. Proteomics 8, 791-798.
74. Kwiatkowski, M.K., Recker, F., Piironen, T., Pettersson, K., Otto, T., Wernli, M., and Tscholl, R. (1998). In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone " of total PSA 4 to 10 ng/mL. Urology 52, 360-365. (Pubitemid 28399898)
75. Kyriakopoulou, L.G., Yousef, G.M., Scorilas, A., Katsaros, D., Massobrio, M., Fracchioli, S., and Diamandis, E.P. (2003). Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin. Biochem. 36, 135-143. (Pubitemid 36287493)
76. Lai, L.C., Erbas, H., Lennard, T.W., and Peaston, R.T. (1996). Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int. J. Cancer 66, 743-746.
77. Lawrence, M.G., Lai, J., and Clements, J.A. (2010). Kallikreins on steroids: structure, function, and hormonal regulation of prostatespecific antigen and the extended kallikrein locus. Endocr. Rev. 31, 407-446.
78. Li, X., Liu, J., Wang, Y., Zhang, L., Ning, L., and Feng, Y. (2009). Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies. Cancer Sci. 100, 601-607.
79. Lilja, H., Ulmert, D., and Vickers, A.J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268-278. (Pubitemid 351430866)
80. Lin, D.L., Whitney, M.C., Yao, Z., and Keller, E.T. (2001). Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res. 7, 1773-1781. (Pubitemid 32708648)
81. Lu, Y., Papagerakis, P., Yamakoshi, Y., Hu, J.C., Bartlett, J.D., and Simmer, J.P. (2008). Functions of KLK4 and MMP-20 in dental enamel formation. Biol. Chem. 389, 695-700. (Pubitemid 352009413)
82. Lundwall, A., Band, V., Blaber, M., Clements, J.A., Courty, Y., Diamandis, E.P., Fritz, H., Lilja, H., Malm, J., Maltais, L.J., et al. (2006). A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387, 637-641. (Pubitemid 43964785)
83. Luo, L.Y., Bunting, P., Scorilas, A., and Diamandis, E.P. (2001a). Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin. Chim. Acta 306, 111-118. (Pubitemid 32244332)
84. Luo, L.Y., Katsaros, D., Scorilas, A., Fracchioli, S., Piccinno, R., Rigault de la Longrais, I.A., Howarth, D.J., and Diamandis, E.P. (2001b). Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res. 7, 2372-2379. (Pubitemid 32751638)
85. Luo, L.Y., Diamandis, E.P., Look, M.P., Soosaipillai, A.P., and Foekens, J.A. (2002). Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br. J. Cancer 86, 1790-1796. (Pubitemid 34712925)
86. Luo, L.Y., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Henrik, A., Stenman, U.H., Massobrio, M., et al. (2003). The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63, 807-811. (Pubitemid 36231980)
87. Magklara, A., Scorilas, A., Catalona, W.J., and Diamandis, E.P. (1999). The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin. Chem. 45, 1960-1966. (Pubitemid 29522004)
88. Magklara, A., Scorilas, A., Stephan, C., Kristiansen, G.O., Hauptmann, S., Jung, K., and Diamandis, E.P. (2000). Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56, 527-532. (Pubitemid 30658202)
89. Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Danese, S., and Diamandis, E.P. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 7, 806-811. (Pubitemid 32708714)
90. Magklara, A., Mellati, A.A., Wasney, G.A., Little, S.P., Sotiropoulou, G., Becker, G.W., and Diamandis, E.P. (2003). Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun. 307, 948-955. (Pubitemid 36871664)
91. Mangé, A., Desmetz, C., Berthes, M.L., Maudelonde, T., and Solassol, J. (2008). Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells. Biochem. Biophys. Res. Commun. 375, 107-112.
92. Mason, S.D. and Joyce, J.A. (2011). Proteolytic networks in cancer. Trends Cell Biol. 21, 228-237.
93. Matsumura, M., Bhatt, A.S., Andress, D., Clegg, N., Takayama, T.K., Craik, C.S., and Nelson, P.S. (2005). Substrates of the prostatespecific serine protease prostase/KLK4 defined by positionalscanning peptide libraries. Prostate 62, 1-13. (Pubitemid 39614288)
94. Mavridis, K. and Scorilas, A. (2010). Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 6, 269-285.
95. Mavridis, K., Avgeris, M., Koutalellis, G., Stravodimos, K., and Scorilas, A. (2010a). Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Sci. 101, 693-699.
96. Mavridis, K., Talieri, M., and Scorilas, A. (2010b). KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol. Chem. 391, 467-474.
97. McIntosh, M.W., Liu, Y., Drescher, C., Urban, N., and Diamandis, E.P. (2007). Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin. Cancer Res. 13, 4422-4428. (Pubitemid 47219709)
98. Mian, O.Y., Wang, S.Z., Zhu, S.Z., Gnanapragasam, M.N., Graham, L., Bear, H.D., and Ginder, G.D. (2011). Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol. Cancer Res. 9, 1152-1162.
99. Michael, I.P., Sotiropoulou, G., Pampalakis, G., Magklara, A., Ghosh, M., Wasney, G., and Diamandis, E.P. (2005). Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 280, 14628-14635. (Pubitemid 40562808)
100. Mikolajczyk, S.D., Millar, L.S., Kumar, A., and Saedi, M.S. (1999). Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int. J. Cancer 81, 438-442. (Pubitemid 29165203)
101. Mize, G.J., Wang, W., and Takayama, T.K. (2008). Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol. Cancer Res. 6, 1043-1051.
102. Mo, L., Zhang, J., Shi, J., Xuan, Q., Yang, X., Qin, M., Lee, C., Klocker, H., Li, Q.Q., and Mo, Z. (2010). Human kallikrein 7 induces epithelial-mesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression. Anticancer Res. 30, 3413-3420.
103. Monti, S., Proietti-Pannunzi, L., Sciarra, A., Lolli, F., Falasca, P., Poggi, M., Celi, F.S., and Toscano, V. (2007). The IGF axis in prostate cancer. Curr. Pharm. Des. 13, 719-727. (Pubitemid 46510747)
104. Nadiminty, N., Lou, W., Lee, S.O., Mehraein-Ghomi, F., Kirk, J.S., Conroy, J.M., Zhang, H., and Gao, A.C. (2006). Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin. Cancer Res. 12, 1420-1430.
105. Nakamura, T., Scorilas, A., Stephan, C., Jung, K., Soosaipillai, A.R., and Diamandis, E.P. (2003a). The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 63, 6543-6546. (Pubitemid 37255209)
106. Nakamura, T., Stephan, C., Scorilas, A., Yousef, G.M., Jung, K., and Diamandis, E.P. (2003b). Quantitative analysis of hippostasin/ KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology 61, 1042-1046. (Pubitemid 36547767)
107. Nam, R.K., Diamandis, E.P., Toi, A., Trachtenberg, J., Magklara, A., Scorilas, A., Papnastasiou, P.A., Jewett, M.A., and Narod, S.A. (2000). Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J. Clin. Oncol. 18, 1036-1042. (Pubitemid 30123780)
108. Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1-22. (Pubitemid 40720363)
109. Obiezu, C.V., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Rigault de la Longrais, I.A., Arisio, R., and Diamandis, E.P. (2001). Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 7, 2380-2386. (Pubitemid 32751639)
110. Oikonomopoulou, K., Hansen, K.K., Baruch, A., Hollenberg, M.D., and Diamandis, E.P. (2008a). Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. Biol. Chem. 389, 747-756. (Pubitemid 352009419)
111. Oikonomopoulou, K., Li, L., Zheng, Y., Simon, I., Wolfert, R.L., Valik, D., Nekulova, M., Simickova, M., Frgala, T., and Diamandis, E.P. (2008b). Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br. J. Cancer 99, 1103-1113.
112. Oikonomopoulou, K., Batruch, I., Smith, C.R., Soosaipillai, A., Diamandis, E.P., and Hollenberg, M.D. (2010a). Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. Biol. Chem. 391, 381-390.
113. Oikonomopoulou, K., Diamandis, E.P., and Hollenberg, M.D. (2010b). Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol. Chem. 391, 299-310.
114. Paliouras, M., Borgono, C., and Diamandis, E.P. (2007). Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 249, 61-79. (Pubitemid 46427999)
115. Pampalakis, G. and Sotiropoulou, G. (2007). Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta 1776, 22-31. (Pubitemid 47332073)
116. Pampalakis, G., Prosnikli, E., Agalioti, T., Vlahou, A., Zoumpourlis, V., and Sotiropoulou, G. (2009). A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 69, 3779-3787.
117. Papachristopoulou, G., Avgeris, M., and Scorilas, A. (2009). Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb. Haemost. 101, 381-387.
118. Papachristopoulou, G., Avgeris, M., Charlaftis, A., and Scorilas, A. (2011). Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. Thromb. Haemost. 105, 131-137.
119. Papadopoulos, I., Sivridis, E., Giatromanolaki, A., and Koukourakis, M.I. (2001). Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin. Cancer Res. 7, 1533-1538. (Pubitemid 32708616)
120. Papageorgis, P., Lambert, A.W., Ozturk, S., Gao, F., Pan, H., Manne, U., Alekseyev, Y.O., Thiagalingam, A., Abdolmaleky, H.M., Lenburg, M., et al. (2010). Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 70, 968-978.
121. Pezzato, E., Sartor, L., Dell'Aica, I., Dittadi, R., Gion, M., Belluco, C., Lise, M., and Garbisa, S. (2004). Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int. J. Cancer 112, 787-792. (Pubitemid 39435263)
122. Pinzani, P., Lind, K., Malentacchi, F., Nesi, G., Salvianti, F., Villari, D., Kubista, M., Pazzagli, M., and Orlando, C. (2008). Prostatespecific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase- quantitative polymerase chain reaction and immunoquantitative polymerase chain reaction. Hum. Pathol. 39, 1474-1482.
123. Plendl, J., Snyman, C., Naidoo, S., Sawant, S., Mahabeer, R., and Bhoola, K.D. (2000). Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem. 381, 1103-1115. (Pubitemid 32000806)
124. Prezas, P., Arlt, M.J., Viktorov, P., Soosaipillai, A., Holzscheiter, L., Schmitt, M., Talieri, M., Diamandis, E.P., Kruger, A., and Magdolen, V. (2006). Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol. Chem. 387, 807-811. (Pubitemid 43964805)
125. Rabien, A., Fritzsche, F., Jung, M., Diamandis, E.P., Loening, S.A., Dietel, M., Jung, K., Stephan, C., and Kristiansen, G. (2008). High expression
126. Rabien, A., Fritzsche, F.R., Jung, M., Tolle, A., Diamandis, E.P., Miller, K., Jung, K., Kristiansen, G., and Stephan, C. (2010). KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int. J. Cancer 127, 2386-2394.
127. Rajah, R., Valentinis, B., and Cohen, P. (1997). Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272, 12181-12188. (Pubitemid 27202802)
128. Ramsay, A.J., Dong, Y., Hunt, M.L., Linn, M., Samaratunga, H., Clements, J.A., and Hooper, J.D. (2008a). Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease- activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J. Biol. Chem. 283, 12293-12304.
129. Ramsay, A.J., Reid, J.C., Adams, M.N., Samaratunga, H., Dong, Y., Clements, J.A., and Hooper, J.D. (2008b). Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol. Chem. 389, 653-668. (Pubitemid 352009411)
130. Rehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, F., and Moreau, T. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 268, 2960-2968. (Pubitemid 32862980)
131. Renehan, A.G., Zwahlen, M., Minder, C., O'Dwyer, S.T., Shalet, S.M., and Egger, M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363, 1346-1353. (Pubitemid 38529873)
132. Renehan, A.G., Harvie, M., and Howell, A. (2006). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr. Relat. Cancer 13, 273-278. (Pubitemid 43886658)
133. Romanov, V.I., Whyard, T., Adler, H.L., Waltzer, W.C., and Zucker, S. (2004). Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen. Cancer Res. 64, 2083-2089. (Pubitemid 38339457)
134. Rowlands, M.A., Gunnell, D., Harris, R., Vatten, L.J., Holly, J.M., and Martin, R.M. (2009). Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and metaanalysis. Int. J. Cancer 124, 2416-2429.
135. Samani, A.A., Yakar, S., LeRoith, D., and Brodt, P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47. (Pubitemid 46220849)
136. Sano, A., Sangai, T., Maeda, H., Nakamura, M., Hasebe, T., and Ochiai, A. (2007). Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int. J. Oncol. 30, 1493-1498.
137. Sauter, E.R., Klein, G., Wagner-Mann, C., and Diamandis, E.P. (2004a). Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. Cancer Detect. Prev. 28, 27-31. (Pubitemid 39403830)
138. Sauter, E.R., Lininger, J., Magklara, A., Hewett, J.E., and Diamandis, E.P. (2004b). Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int. J. Cancer 108, 588-591. (Pubitemid 38036660)
139. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328.
140. Scorilas, A., Borgono, C.A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., and Diamandis, E.P. (2004). Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 22, 678-685. (Pubitemid 41095071)
141. Shigemasa, K., Gu, L., Tanimoto, H., O'Brien, T.J., and Ohama, K. (2004a). Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin. Cancer Res. 10, 2766-2770. (Pubitemid 38509153)
142. Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L.J., O'Brien, T.J., and Ohama, K. (2004b). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol. Rep. 11, 1153-1159.
143. Shih Ie, M., Salani, R., Fiegl, M., Wang, T.L., Soosaipillai, A., Marth, C., Muller-Holzner, E., Gastl, G., Zhang, Z., and Diamandis, E.P. (2007). Ovarian cancer specific kallikrein profile in effusions. Gynecol. Oncol. 105, 501-507. (Pubitemid 46590345)
144. Sotiropoulou, G., Rogakos, V., Tsetsenis, T., Pampalakis, G., Zafiropoulos, N., Simillides, G., Yiotakis, A., and Diamandis, E.P. (2003). Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. 13, 381-391. (Pubitemid 38166369)
145. Stephan, C., Jung, K., Lein, M., and Diamandis, E.P. (2007). PSA and other tissue kallikreins for prostate cancer detection. Eur. J. Cancer. 43, 1918-1926. (Pubitemid 47287733)
146. Steuber, T., Vickers, A.J., Serio, A.M., Vaisanen, V., Haese, A., Pettersson, K., Eastham, J.A., Scardino, P.T., Huland, H., and Lilja, H. (2007). Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin. Chem. 53, 233-240. (Pubitemid 46338267)
147. Sun, X.Y., Donald, S.P., and Phang, J.M. (2001). Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22, 1775-1780. (Pubitemid 33064841)
148. Takayama, T.K., Fujikawa, K., and Davie, E.W. (1997). Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272, 21582-21588. (Pubitemid 27374034)
149. Takayama, T.K., McMullen, B.A., Nelson, P.S., Matsumura, M., and Fujikawa, K. (2001). Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinasetype plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40, 15341-15348. (Pubitemid 33151949)
150. Talieri, M., Diamandis, E.P., Gourgiotis, D., Mathioudaki, K., and Scorilas, A. (2004). Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb. Haemost. 91, 180-186. (Pubitemid 38111235)
151. Talieri, M., Devetzi, M., Scorilas, A., Prezas, P., Ardavanis, A., Apostolaki, A., and Karameris, A. (2011). Evaluation of kallikrein- related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression. Anticancer Res. 31, 3093-3100.
152. Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
153. Thomadaki, H., Mavridis, K., Talieri, M., and Scorilas, A. (2009). Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb. Haemost. 101, 373-380.
154. Ueda, T., Bruchovsky, N., and Sadar, M.D. (2002). Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277, 7076-7085. (Pubitemid 34959964)
155. Ulmert, D., O'Brien, M.F., Bjartell, A.S., and Lilja, H. (2009). Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat. Rev. Urol. 6, 384-391.
156. Veveris-Lowe, T.L., Lawrence, M.G., Collard, R.L., Bui, L., Herington, A.C., Nicol, D.L., and Clements, J.A. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat. Cancer 12, 631-643. (Pubitemid 41482997)
157. Wang, W., Mize, G.J., Zhang, X., and Takayama, T.K. (2010). Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1. Int. J. Cancer 126, 599-610.
158. Webber, M.M., Waghray, A., and Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089-1094.
159. Werle, E., Gotze, W., and Keppler, A. (1937). Über die Wirkung des Kallikreins aus dem isolierten Darm undüber eine neue darmkontrahierende Substanz. Biochem. J. 289, 217-233.
160. Werner, H. and Bruchim, I. (2009). The insulin-like growth factor-I receptor as an oncogene. Arch. Physiol. Biochem. 115, 58-71.
161. Whitbread, A.K., Veveris-Lowe, T.L., Lawrence, M.G., Nicol, D.L., and Clements, J.A. (2006). The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biol. Chem. 387, 707-714. (Pubitemid 43964792)
162. White, N.M., Mathews, M., Yousef, G.M., Prizada, A., Popadiuk, C., and Dore, J.J. (2009). KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br. J. Cancer 101, 1107-1113.
163. White, N.M., Chow, T.F., Mejia-Guerrero, S., Diamandis, M., Rofael, Y., Faragalla, H., Mankaruous, M., Gabril, M., Girgis, A., and Yousef, G.M. (2010). Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br. J. Cancer 102, 1244-1253.
164. Wolf, W.C., Evans, D.M., Chao, L., and Chao, J. (2001). A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am. J. Pathol. 159, 1797-1805. (Pubitemid 33062522)
165. Xi, Z., Kaern, J., Davidson, B., Klokk, T.I., Risberg, B., Trope, C., and Saatcioglu, F. (2004). Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol. Oncol. 94, 80-85. (Pubitemid 38950502)
166. Yamasaki, K., Schauber, J., Coda, A., Lin, H., Dorschner, R.A., Schechter, N.M., Bonnart, C., Descargues, P., Hovnanian, A., and Gallo, R.L. (2006). Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20, 2068-2080. (Pubitemid 44953906)
167. Yonou, H., Aoyagi, Y., Kanomata, N., Kamijo, T., Oda, T., Yokose, T., Hasebe, T., Nagai, K., Hatano, T., Ogawa, Y., et al. (2001). Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem. Biophys. Res. Commun. 289, 1082-1087. (Pubitemid 34076301)
168. Yoon, H., Laxmikanthan, G., Lee, J., Blaber, S.I., Rodriguez, A., Kogot, J.M., Scarisbrick, I.A., and Blaber, M. (2007). Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J. Biol. Chem. 282, 31852-31864. (Pubitemid 350106429)
169. Yoon, H., Blaber, S.I., Debela, M., Goettig, P., Scarisbrick, I.A., and Blaber, M. (2009). A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol. Chem. 390, 373-377.
170. Yousef, G.M. (2008). microRNAs: a new frontier in kallikrein research. Biol. Chem. 389, 689-694. (Pubitemid 352009401)
171. Yousef, G.M. and Diamandis, E.P. (2009). The human kallikrein gene family: new biomarkers for ovarian cancer. Cancer Treat. Res. 149, 165-187.
172. Yousef, G.M., Chang, A., Scorilas, A., and Diamandis, E.P. (2000). Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun. 276, 125-133.
173. Yousef, G.M., Kyriakopoulou, L.G., Scorilas, A., Fracchioli, S., Ghiringhello, B., Zarghooni, M., Chang, A., Diamandis, M., Giardina, G., Hartwick, W.J., et al. (2001). Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61, 7811-7818. (Pubitemid 33049369)
174. Yousef, G.M., Borgono, C.A., Scorilas, A., Ponzone, R., Biglia, N., Iskander, L., Polymeris, M.E., Roagna, R., Sismondi, P., and Diamandis, E.P. (2002a). Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br. J. Cancer 87, 1287-1293. (Pubitemid 36009135)
175. Yousef, G.M., Scorilas, A., Chang, A., Rendl, L., Diamandis, M., Jung, K., and Diamandis, E.P. (2002b). Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 51, 126-132.
176. Yousef, G.M., Scorilas, A., Kyriakopoulou, L.G., Rendl, L., Diamandis, M., Ponzone, R., Biglia, N., Giai, M., Roagna, R., Sismondi, P., et al. (2002c). Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin. Chem. 48, 1241-1250. (Pubitemid 34809832)
177. Yousef, G.M., Scorilas, A., Magklara, A., Memari, N., Ponzone, R., Sismondi, P., Biglia, N., Abd Ellatif, M., and Diamandis, E.P. (2002d). The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br. J. Cancer 87, 1294-1300. (Pubitemid 36009136)
178. Yousef, G.M., Fracchioli, S., Scorilas, A., Borgono, C.A., Iskander, L., Puopolo, M., Massobrio, M., Diamandis, E.P., and Katsaros, D. (2003a). Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am. J. Clin. Pathol. 119, 346-355. (Pubitemid 37047856)
179. Yousef, G.M., Polymeris, M.E., Grass, L., Soosaipillai, A., Chan, P.C., Scorilas, A., Borgono, C., Harbeck, N., Schmalfeldt, B., Dorn, J., et al. (2003b). Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63, 3958-3965. (Pubitemid 36917912)
180. Yousef, G.M., Scorilas, A., Katsaros, D., Fracchioli, S., Iskander, L., Borgono, C., Rigault de la Longrais, I.A., Puopolo, M., Massobrio, M., and Diamandis, E.P. (2003c). Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 21, 3119-3126. (Pubitemid 46606293)
181. Yousef, G.M., Scorilas, A., Nakamura, T., Ellatif, M.A., Ponzone, R., Biglia, N., Maggiorotto, F., Roagna, R., Sismondi, P., and Diamandis, E.P. (2003d). The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res. Treat. 78, 149-158. (Pubitemid 36433908)
182. Yousef, G.M., Stephan, C., Scorilas, A., Ellatif, M.A., Jung, K., Kristiansen, G., Jung, M., Polymeris, M.E., and Diamandis, E.P. (2003e). Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56, 287-292. (Pubitemid 36988749)
183. Yu, H., Diamandis, E.P., Levesque, M., Giai, M., Roagna, R., Ponzone, R., Sismondi, P., Monne, M., and Croce, C.M. (1996). Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res. Treat. 40, 171-178. (Pubitemid 26283509)
184. Yu, H., Levesque, M.A., Clark, G.M., and Diamandis, E.P. (1998). Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res. 4, 1489-1497. (Pubitemid 28265233)
185. Zhang, R., Shi, H., Chen, Z., Feng, W., Zhang, H., and Wu, K. (2012). Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells. Mol. Med. Report 5, 256-259.
186. Zhang, Y., Bhat, I., Zeng, M., Jayal, G., Wazer, D.E., Band, H., and Band, V. (2006). Human kallikrein 10, a predictive marker for breast cancer. Biol. Chem. 387, 715-721. (Pubitemid 43964793)
187. Zheng, Y., Katsaros, D., Shan, S.J., de la Longrais, I.R., Porpiglia, M., Scorilas, A., Kim, N.W., Wolfert, R.L., Simon, I., Li, L., Feng, Z., et al. (2007). A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin. Cancer Res. 13, 6984-6992. (Pubitemid 350276879)